Page last updated: 2024-10-25

clenbuterol and Glioma

clenbuterol has been researched along with Glioma in 1 studies

Clenbuterol: A substituted phenylaminoethanol that has beta-2 adrenomimetic properties at very low doses. It is used as a bronchodilator in asthma.
clenbuterol : A substituted aniline that is 2,6-dichloroaniline in which the hydrogen at position 4 has been replaced by a 2-(tert-butylamino)-1-hydroxyethyl group.

Glioma: Benign and malignant central nervous system neoplasms derived from glial cells (i.e., astrocytes, oligodendrocytes, and ependymocytes). Astrocytes may give rise to astrocytomas (ASTROCYTOMA) or glioblastoma multiforme (see GLIOBLASTOMA). Oligodendrocytes give rise to oligodendrogliomas (OLIGODENDROGLIOMA) and ependymocytes may undergo transformation to become EPENDYMOMA; CHOROID PLEXUS NEOPLASMS; or colloid cysts of the third ventricle. (From Escourolle et al., Manual of Basic Neuropathology, 2nd ed, p21)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
McCauslin, CS1
Heath, V1
Colangelo, AM1
Malik, R1
Lee, S1
Mallei, A1
Mocchetti, I1
Johnson, PF1

Other Studies

1 other study available for clenbuterol and Glioma

ArticleYear
CAAT/enhancer-binding protein delta and cAMP-response element-binding protein mediate inducible expression of the nerve growth factor gene in the central nervous system.
    The Journal of biological chemistry, 2006, Jun-30, Volume: 281, Issue:26

    Topics: Adrenergic beta-Agonists; Animals; Brain; CCAAT-Enhancer-Binding Protein-beta; CCAAT-Enhancer-Bindin

2006